David H Margolin

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

E. Havrdová, G. Giovannoni, D. Margolin, 2017, Multiple sclerosis.